OA10893A - Treatment of a hemoglobinopathy - Google Patents
Treatment of a hemoglobinopathy Download PDFInfo
- Publication number
- OA10893A OA10893A OA9800189A OA9800189A OA10893A OA 10893 A OA10893 A OA 10893A OA 9800189 A OA9800189 A OA 9800189A OA 9800189 A OA9800189 A OA 9800189A OA 10893 A OA10893 A OA 10893A
- Authority
- OA
- OAPI
- Prior art keywords
- patient
- gas
- therapeutic
- ppm
- oxygen
- Prior art date
Links
- 208000034737 hemoglobinopathy Diseases 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 59
- 239000001301 oxygen Substances 0.000 claims abstract description 59
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 47
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 47
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229910002091 carbon monoxide Inorganic materials 0.000 claims abstract description 39
- 230000002829 reductive effect Effects 0.000 claims abstract description 11
- 239000007789 gas Substances 0.000 claims description 87
- 230000001225 therapeutic effect Effects 0.000 claims description 63
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 22
- 230000007423 decrease Effects 0.000 claims description 13
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 208000000859 Sickle cell trait Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 101000886863 Phacoides pectinatus Hemoglobin-1 Proteins 0.000 claims description 5
- 101000886862 Phreagena soyoae Globin-1 Proteins 0.000 claims description 5
- 108010047389 hemoglobin D Proteins 0.000 claims description 5
- 238000011065 in-situ storage Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000009935 nitrosation Effects 0.000 claims description 4
- 238000007034 nitrosation reaction Methods 0.000 claims description 4
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 claims description 3
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 229940100563 gas for inhalation Drugs 0.000 claims description 3
- 229960002460 nitroprusside Drugs 0.000 claims description 3
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 239000000779 smoke Substances 0.000 claims description 2
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 3
- 101100537948 Mus musculus Trir gene Proteins 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 abstract description 27
- 238000000034 method Methods 0.000 abstract description 26
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 14
- 229960003753 nitric oxide Drugs 0.000 abstract 1
- 239000002840 nitric oxide donor Substances 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 15
- 230000029058 respiratory gaseous exchange Effects 0.000 description 12
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 9
- 108010061951 Methemoglobin Proteins 0.000 description 8
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 5
- 208000002903 Thalassemia Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 4
- 108010064719 Oxyhemoglobins Proteins 0.000 description 4
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 4
- -1 aminoacid glutamate Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960001456 adenosine triphosphate Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 108010009903 hemoglobin Kansas Proteins 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002496 oximetry Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- OMDHRFLPMCNHCN-REOHCLBHSA-N (2r)-2-amino-3-nitrosulfanylpropanoic acid Chemical compound OC(=O)[C@@H](N)CS[N+]([O-])=O OMDHRFLPMCNHCN-REOHCLBHSA-N 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000009120 supportive therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 101100295884 Aedes aegypti SGPRor7 gene Proteins 0.000 description 1
- 229920006384 Airco Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000136406 Comones Species 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 241000630665 Hada Species 0.000 description 1
- 208000034502 Haemoglobin C disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 101150041122 Orco gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- ZPGKBYMJBZKMAM-UHFFFAOYSA-I calcium;potassium;barium(2+);pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[K+].[Ca+2].[Ba+2] ZPGKBYMJBZKMAM-UHFFFAOYSA-I 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 108010073937 hemoglobin Arab Proteins 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- MDKQJOKKKZNQDG-UHFFFAOYSA-N n,n'-dimethylhexane-1,6-diamine Chemical compound CNCCCCCCNC MDKQJOKKKZNQDG-UHFFFAOYSA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1488696P | 1996-04-05 | 1996-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10893A true OA10893A (en) | 2001-10-11 |
Family
ID=21768361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA9800189A OA10893A (en) | 1996-04-05 | 1998-10-02 | Treatment of a hemoglobinopathy |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5885621A (fr) |
| EP (1) | EP0914103B1 (fr) |
| JP (1) | JP2000510448A (fr) |
| CN (1) | CN1208053C (fr) |
| AP (1) | AP897A (fr) |
| AT (1) | ATE331505T1 (fr) |
| AU (1) | AU720686B2 (fr) |
| BR (1) | BR9708601A (fr) |
| CA (1) | CA2251530C (fr) |
| DE (1) | DE69736230T2 (fr) |
| DK (1) | DK0914103T3 (fr) |
| ES (1) | ES2267141T3 (fr) |
| OA (1) | OA10893A (fr) |
| PT (1) | PT914103E (fr) |
| WO (1) | WO1997037644A1 (fr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| US6197745B1 (en) | 1995-09-15 | 2001-03-06 | Duke University | Methods for producing nitrosated hemoglobins and therapeutic uses therefor |
| US6627738B2 (en) | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
| US6911427B1 (en) | 1995-09-15 | 2005-06-28 | Duke University | No-modified hemoglobins and uses therefore |
| US8128963B2 (en) * | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
| US6656452B1 (en) | 1997-10-21 | 2003-12-02 | The General Hospital Corporation | Use of inhaled NO as anti-inflammatory agent |
| US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
| CA2254645A1 (fr) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Methode et appareil pour traiter les infections respiratoires par l'inhalation d'oxyde nitrique |
| US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
| FR2794647A1 (fr) * | 1999-06-11 | 2000-12-15 | Centre Nat Rech Scient | Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules |
| US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
| US6601580B1 (en) * | 2000-06-28 | 2003-08-05 | The General Hospital Corporation | Enhancing therapeutic effectiveness of nitric oxide inhalation |
| FR2812197B1 (fr) * | 2000-07-27 | 2003-01-03 | Air Liquide Sante Int | Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches |
| FR2816212A1 (fr) * | 2000-11-03 | 2002-05-10 | Air Liquide Sante Int | Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire |
| US7122018B2 (en) * | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
| US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
| US7335181B2 (en) * | 2000-12-26 | 2008-02-26 | Pulmonox Technologies Corporation | Nitric oxide decontamination of the upper respiratory tract |
| GB0111872D0 (en) * | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
| ES2316583T3 (es) * | 2001-06-21 | 2009-04-16 | Beth Israel Deaconess Medical Center, Inc. | El monoxido de carbono mejora los resultados de trasplantes de tejidos y organos y suprime la adoptosis. |
| GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
| US7968605B2 (en) * | 2002-02-04 | 2011-06-28 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
| US20080026984A1 (en) * | 2002-02-04 | 2008-01-31 | Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
| WO2003066067A2 (fr) * | 2002-02-04 | 2003-08-14 | Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. | Methode permettant de traiter un mammifere par administration d'un compose liberant du monoxyde de carbone, composes liberant ledit monoxyde de carbone et compositions pharmaceutiques associees |
| EP1480658B1 (fr) * | 2002-02-13 | 2017-01-25 | Beth Israel Deaconess Medical Center, Inc. | Procedes concernant le traitement d'une affection vasculaire |
| US8097585B2 (en) | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
| RS91104A (en) * | 2002-04-15 | 2007-02-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education, | Methods of treating necrotizing enterocolitis |
| ES2546280T3 (es) * | 2002-04-15 | 2015-09-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Monóxido de carbono para su uso en un método para tratar íleo |
| RS99304A (en) | 2002-05-17 | 2007-04-10 | Yale University, | Methods of treating hepatitis |
| EP1509237A4 (fr) * | 2002-06-05 | 2006-07-12 | Univ Yale | Methodes de traitement de l'angiogenese, de la croissance tumorale et de metastases |
| US20040131703A1 (en) * | 2002-06-21 | 2004-07-08 | Bach Fritz H. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
| US7531133B2 (en) * | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
| US20040228930A1 (en) * | 2002-11-07 | 2004-11-18 | Billiar Timothy R. | Treatment for hemorrhagic shock |
| GB2395432B (en) * | 2002-11-20 | 2005-09-14 | Northwick Park Inst For Medica | Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs |
| AU2004255268B2 (en) * | 2003-07-09 | 2010-04-01 | Loma Linda University | Use of nitrite salts for the treatment of cardiovascular conditions |
| WO2005077005A2 (fr) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Amelioration de l'efficacite d'un gaz therapeutique inhale |
| MXPA06013111A (es) | 2004-05-11 | 2007-05-23 | Sensormedics Corp | Dosificacion intermitente de gas de oxido nitrico. |
| US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
| US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
| US20070154570A1 (en) * | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
| US8557300B2 (en) * | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
| US7523752B2 (en) | 2005-09-21 | 2009-04-28 | Ino Therapeutics, Llc | System and method of administering a pharmaceutical gas to a patient |
| US8893717B2 (en) | 2005-09-21 | 2014-11-25 | Ino Therapeutics Llc | Systems and methods of administering a pharmaceutical gas to a patient |
| US20070116785A1 (en) * | 2005-11-18 | 2007-05-24 | Miller Christopher C | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
| WO2007073226A1 (fr) * | 2005-12-20 | 2007-06-28 | Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda | Procede de traitement d'un mammifere par l'administration d'un compose capable de liberer du co |
| GB0601394D0 (en) | 2006-01-24 | 2006-03-01 | Hemocorm Ltd | Therapeutic delivery of carbon monoxide |
| US8079998B2 (en) * | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
| EP2099463B1 (fr) * | 2006-11-07 | 2014-07-16 | The General Hospital Corporation | Atténuation de la vasoconstriction induite par un transporteur d'oxygène vasoactif |
| US20080193566A1 (en) * | 2007-02-09 | 2008-08-14 | Miller Christopher C | Use of high dose concentrations of gaseous nitric oxide |
| EP2237788A4 (fr) * | 2007-12-27 | 2013-06-05 | Aires Pharmaceuticals Inc | Composés permettant d'obtenir du nitrite et de l'oxyde nitrique aérosolisés et leurs utilisations |
| BRPI0924534B1 (pt) | 2009-05-27 | 2022-09-27 | Mallinckrodt Hospital Products IP Limited | Dispositivo de contenção de droga indexado |
| CA3130908A1 (fr) | 2009-06-30 | 2010-12-30 | Mallinckrodt Hospital Products IP Limited | Procedes destines au traitement des nouveau-nes a terme ou presque a terme atteints d'une insuffisance respiratoire hypoxique associee a des signes cliniques ou echocardiographiques d'hypertension pulmonaire |
| US20120201906A1 (en) * | 2009-09-08 | 2012-08-09 | Reynolds James D | Novel medical uses for no and no donor compounds |
| EP2699242B1 (fr) | 2011-04-19 | 2017-11-01 | Alfama, Inc. | Molécules libérant du monoxyde de carbone et utilisations de celles-ci |
| EP2734235B1 (fr) | 2011-07-21 | 2017-03-22 | Alfama, Inc. | Molécules libérant du ruthénium-monoxyde de carbone et utilisations de celles-ci |
| EP3650408A1 (fr) | 2011-10-03 | 2020-05-13 | NitricGen, Inc. | Appareil et procédé de génération d'oxyde nitrique dans des quantités contrôlées et précises |
| CN104159591A (zh) | 2011-11-07 | 2014-11-19 | 通用医疗公司 | 红细胞的处理 |
| MX368858B (es) | 2012-03-15 | 2019-10-18 | Mallinckrodt Hospital Products Ip Ltd | Metodos para administrar altas concentraciones de oxido nitrico. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
| US5380945A (en) * | 1989-06-21 | 1995-01-10 | Abbott Laboratories | Guanidino compounds as regulators of nitric oxide synthase |
| US5155137A (en) * | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
| DK0560928T3 (da) * | 1990-12-05 | 1997-12-01 | Gen Hospital Corp | Anordninger til behandling af pulmonal vasokonstriktion og astma |
| DE69424560T2 (de) * | 1993-11-02 | 2001-01-18 | Us Health | Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden |
-
1997
- 1997-04-03 ES ES97920137T patent/ES2267141T3/es not_active Expired - Lifetime
- 1997-04-03 AP APAP/P/1998/001358A patent/AP897A/en active
- 1997-04-03 AU AU24403/97A patent/AU720686B2/en not_active Ceased
- 1997-04-03 DK DK97920137T patent/DK0914103T3/da active
- 1997-04-03 PT PT97920137T patent/PT914103E/pt unknown
- 1997-04-03 WO PCT/US1997/005633 patent/WO1997037644A1/fr active IP Right Grant
- 1997-04-03 CA CA002251530A patent/CA2251530C/fr not_active Expired - Fee Related
- 1997-04-03 CN CNB971953066A patent/CN1208053C/zh not_active Expired - Fee Related
- 1997-04-03 DE DE69736230T patent/DE69736230T2/de not_active Expired - Lifetime
- 1997-04-03 EP EP97920137A patent/EP0914103B1/fr not_active Expired - Lifetime
- 1997-04-03 AT AT97920137T patent/ATE331505T1/de active
- 1997-04-03 JP JP09536357A patent/JP2000510448A/ja not_active Ceased
- 1997-04-03 BR BR9708601A patent/BR9708601A/pt not_active Application Discontinuation
- 1997-04-04 US US08/832,913 patent/US5885621A/en not_active Expired - Lifetime
-
1998
- 1998-10-02 OA OA9800189A patent/OA10893A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP9801358A0 (en) | 1998-12-31 |
| AU2440397A (en) | 1997-10-29 |
| DK0914103T3 (da) | 2006-10-23 |
| DE69736230D1 (de) | 2006-08-10 |
| ATE331505T1 (de) | 2006-07-15 |
| DE69736230T2 (de) | 2007-05-31 |
| CN1208053C (zh) | 2005-06-29 |
| AP897A (en) | 2000-11-17 |
| CA2251530C (fr) | 2002-11-19 |
| JP2000510448A (ja) | 2000-08-15 |
| EP0914103B1 (fr) | 2006-06-28 |
| CN1227485A (zh) | 1999-09-01 |
| US5885621A (en) | 1999-03-23 |
| EP0914103A1 (fr) | 1999-05-12 |
| PT914103E (pt) | 2006-09-29 |
| EP0914103A4 (fr) | 2003-09-03 |
| BR9708601A (pt) | 1999-08-03 |
| WO1997037644A1 (fr) | 1997-10-16 |
| ES2267141T3 (es) | 2007-03-01 |
| CA2251530A1 (fr) | 1997-10-16 |
| AU720686B2 (en) | 2000-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0914103B1 (fr) | Traitement d'un type d'hemoglobinose | |
| EP1229954B1 (fr) | Techniques de traitement de maladies cardio-respiratoires a l'aide de composes renfermant un groupe no | |
| Head et al. | Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. | |
| JP3718491B2 (ja) | 吸入用装置 | |
| Young et al. | Effect of low concentrations of ozone on pulmonary function in man | |
| Goldbaum et al. | Mechanism of the toxic action of carbon monoxide | |
| Jacobs et al. | Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury | |
| Santiago et al. | Mechanism of the ventilatory response to carbon monoxide. | |
| Hedley-Whyte et al. | Oxygen therapy | |
| Geller et al. | Cyanide toxicity from acetonitrile-containing false nail remover | |
| Santiago et al. | The effect of anemia on the ventilatory response to transient and steady-state hypoxia. | |
| Albertson et al. | A case of fatal sodium azide ingestion | |
| Stewart et al. | Acute intoxication with methylchloroform | |
| Higenbottam | Inhaled nitric oxide: a magic bullet? | |
| Miller et al. | Mechanism of erythropoietin production by cobaltous chloride | |
| EP1712226A2 (fr) | Traitement d'un Hemoglobinopathy | |
| Bigelow et al. | The effect of oxygen breathing on arterial blood gases in patients with chronic airway obstruction living at 5,200 feet | |
| HIKASA et al. | Sevoflurane anesthesia following administration of atropine-guaifenesin-thiopental in spontaneous-breathing adult cattle | |
| Ichinose et al. | Inhaled nitric oxide—current practice and future potential uses and development | |
| MXPA98008195A (es) | Tratamiento de una hemoglobinopatia | |
| Ten Eyck et al. | Comparison of nitrite treatment and stroma-free methemoglobin solution as antidotes for cyanide poisoning in a rat model | |
| Hubmayr et al. | Acute and long-term effects of Fluosol-DA 20% on respiratory system mechanics and diffusion capacity in dogs | |
| Grover et al. | Inhaled Nitric Oxide Therapy | |
| Leiter et al. | Hyperoxic ventilatory responses of high altitude acclimatized cats |